【制药网 行业动态】近日,圣华曦药业的乌帕替尼缓释片上市申请获 CDE 受理,为该药物领域竞争再添变数。有数据显示,截至2025年,已有9家企业提交仿制上市申请,包括福元医药、石药集团、复星万邦等,目前共有16家企业正在争夺首仿。乌帕替尼是由艾伯维(AbbVie)公司自主研发的新一代选择性和可逆性 JAK1 抑制剂,通过阻断 JAK-STAT 信号通路中 Janus 激酶的活性起作用,该信号通路在...
Source Link【制药网 行业动态】近日,圣华曦药业的乌帕替尼缓释片上市申请获 CDE 受理,为该药物领域竞争再添变数。有数据显示,截至2025年,已有9家企业提交仿制上市申请,包括福元医药、石药集团、复星万邦等,目前共有16家企业正在争夺首仿。乌帕替尼是由艾伯维(AbbVie)公司自主研发的新一代选择性和可逆性 JAK1 抑制剂,通过阻断 JAK-STAT 信号通路中 Janus 激酶的活性起作用,该信号通路在...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.